Karolinska Development announces preliminary portfolio valuation for the January-March 2015 Interim Report

Karolinska Development continues to focus on the portfolio companies that have possibility to generate attractive returns, while finding constructive solutions for the other portfolio companies. 

Following decisions to discontinue further investment in Pergamum AB, Umecrine Mood AB and NeoDynamics AB (opportunistic portfolio companies) and after exploring several options, Karolinska Development has decided to fully write off these companies. Pergamum value is written off with the amount of SEK 120.2 million, Umecrine Mood with the amount of SEK 58.9 million and NeoDynamics AB with the amount of SEK 9.7 million – all compared to the year-end 2014 valuations. Additional adjustments of fair value of the portfolio amount to SEK -36.4 million.

"The Board and management of Karolinska Development take a rigorous approach to the management of the portfolio to ensure that our expertise and capital are focused on the companies that have the potential to deliver most value for our shareholders. Furthermore, we are evaluating the possibility to change the portfolio valuation principles.  Currently, the major part of the reported fair value is based on the DCF method (discounted cash flow).  This method has been proven difficult for early stage companies where future cash flows and success rates are associated with high levels of uncertainty. We will together with the auditors look into alternatives that are more transparent and less sensitive to incidental variations that have a high impact on valuation," comments Karolinska Development CEO, Jim Van heusden. 

Further details will be disclosed in the January-March 2015 Interim Report, to be released on May 6th, 2015 and followed by a teleconference and webcast arranged later during that day.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.